Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone
- PMID: 1533661
- DOI: 10.1016/s0022-3476(05)80232-x
Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone
Abstract
We evaluated height prognosis and therapeutic efficacy of long-term, combination therapy with gonadotropin releasing-hormone agonist and growth hormone (GH) in five children (three girls) with coexistent precocious puberty and GH deficiency. Their clinical characteristics and growth response were compared with those of 12 girls with idiopathic true precocious puberty and eight prepubertal GH-deficient children (one girl). Precocious GH-deficient subjects were older than the precocious GH-sufficient children (9.5 +/- 1.8 years vs 6.5 +/- 1.3 years; mean +/- SD), but bone ages were comparable (12 +/- 3.7 years vs 10 +/- 0.9 years); their chronologic age was similar to that of the prepubertal GH-deficient children (9.6 +/- 2.1 years), but bone age was significantly more advanced (6.9 +/- 2.3 years). The mean height velocity of the prepubertal GH-deficient children (3.8 +/- 1.5 cm/yr) was lower than that of the precocious GH-deficient subjects (6.7 +/- 1.6 cm/yr) and the precocious GH-sufficient children (9.5 +/- 2.9 cm/yr). Baseline adult height prediction z scores were significantly lower in the precocious GH-deficient children (-3.7 +/- 1.0) than in either the precocious GH-sufficient children (-2.2 +/- 1.0) or the prepubertal GH-deficient subjects (-1.5 +/- 0.8). During therapy with gonadotropin releasing-hormone agonist, growth rates slowed to an average of 3.7 cm/yr in the precocious GH-deficient children but increased after the addition of GH to 7.4 cm during the first year of combination therapy. After 2 to 3 years of combination therapy, height predictions increased an average of 10 cm, compared with an increase of 2.8 cm in the precocious GH-sufficient group treated with gonadotropin releasing-hormone agonist alone. We conclude that combination treatment with gonadotropin releasing-hormone agonist and GH improves the height prognosis of children with coexistent true precocious puberty and GH deficiency, but falls short of achieving normal adult height potential.
Similar articles
-
Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience.Pediatrics. 1999 Oct;104(4 Pt 2):1014-8. Pediatrics. 1999. PMID: 10506254
-
Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.Clin Endocrinol (Oxf). 1998 Aug;49(2):197-202. doi: 10.1046/j.1365-2265.1998.00499.x. Clin Endocrinol (Oxf). 1998. PMID: 9828907 Clinical Trial.
-
Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.J Clin Endocrinol Metab. 2000 Feb;85(2):619-22. doi: 10.1210/jcem.85.2.6387. J Clin Endocrinol Metab. 2000. PMID: 10690865 Clinical Trial.
-
Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis.Medicine (Baltimore). 2014 Dec;93(27):e260. doi: 10.1097/MD.0000000000000260. Medicine (Baltimore). 2014. PMID: 25501098 Free PMC article. Review.
-
Combined therapy with luteinizing hormone releasing hormone agonist (LHRHa) and growth hormone (GH) in central precocious puberty.Acta Biomed. 2005 Sep;76(2):73-8. Acta Biomed. 2005. PMID: 16350551 Review.
Cited by
-
Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls.Front Endocrinol (Lausanne). 2022 Dec 14;13:1085385. doi: 10.3389/fendo.2022.1085385. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36589818 Free PMC article.
-
Gonadotrophin-releasing hormone agonists. A guide to use and selection.Drugs. 1994 Jul;48(1):41-58. doi: 10.2165/00003495-199448010-00005. Drugs. 1994. PMID: 7525194 Review.
-
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.Drugs. 1994 Dec;48(6):930-67. doi: 10.2165/00003495-199448060-00008. Drugs. 1994. PMID: 7533699 Review.
-
Should Skeletal Maturation Be Manipulated for Extra Height Gain?Front Endocrinol (Lausanne). 2021 Dec 16;12:812196. doi: 10.3389/fendo.2021.812196. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34975773 Free PMC article. Review.
-
Sex steroid priming in short stature children unresponsive to GH stimulation tests: Why, who, when and how.Front Endocrinol (Lausanne). 2022 Nov 29;13:1072271. doi: 10.3389/fendo.2022.1072271. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36523598 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical